Mar 03, 2023

CFO and Company Secretary Appointment (ASX Announcement)

CFO and Company Secretary Appointment (ASX Announcement)

Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.

Justin has extensive corporate finance and leadership experience in the biopharmaceutical, food, and agricultural sectors for both ASX-listed and private companies. He is currently CFO at Paradigm Biopharmaceuticals having joined the company in 2020. During his time at Paradigm he has also worked closely with, and provided support to, the company secretarial function.

Justin also worked at CSL for over 9 years where he held a number of senior financial and leadership roles, including 5 years as Divisional CFO at CSL Plasma in the United States (US). CSL Plasma is a leader in plasma collection and now operates in the US, Europe, and China with over 15,000 employees. As Divisional CFO, Justin provided financial and strategic support to the organisation during a period of significant business expansion where the number of collection centres in the US increased from 65 to 130. He also led and contributed to a number of finance and operational initiatives which lowered operating costs and enabled organisational growth during this expansion period.

Justin was later CSL Limited’s Finance Integration Lead for the $250 million Novartis Influenza Acquisition in 2015. In this role, Justin led a team of finance staff spread across the US, Germany and Australia, to deliver all aspects of finance integration for the newly formed organisation, Seqirus.

Prior to joining Paradigm Biopharmaceuticals, Justin was CFO at Diver Foods - Australia’s largest privately held manufacturer of cereal and muesli bars - where he was responsible for financial performance, as well as sourcing and supply chain. He also worked as Group Finance Manager at the ASX-listed Costa Group, which has a market capitalisation of more than $1 billion and revenues of ~$1 billion. At Costa Group Justin had responsibility for a number of key parts of the finance function including treasury management, financial planning and reporting, compliance, and capital control.

Justin is a Certified Practicing Accountant (CPA). He holds a Master of Professional Accounting and a Bachelor of Business. He has also completed company secretary training through the Governance Institute of Australia and the AICD.

Dr Jackie Fairley, Starpharma CEO, said: “Justin is an accomplished CFO and corporate leader with more than 15 years’ experience in finance leadership roles, with the majority being in the healthcare and pharmaceutical sector. He has extensive industry knowledge and international experience having worked across large global businesses and smaller growing companies, including a number of ASX-listed companies during periods of rapid growth. Justin is an excellent addition to Starpharma’s Executive Team, and we look forward to welcoming him in April.”

Justin Cahill said: “I am excited to be joining Starpharma as CFO and Company Secretary, having followed the company for a number of years. I am impressed by Starpharma’s deep portfolio of oncology assets, global partnerships, and marketed products as well as the Company’s positive culture.”  

For the full announcement, please see here.



 This contains certain forward-looking statements.